XenoPort accuses GSK of Horizant marketing breach; NICE gives final rejection to 3 cancer meds;

@FiercePharma: With pharma racing after rare diseases, the gov't has to step in to back antibiotics development--AP. Story | Follow @FiercePharma

> XenoPort has accused GlaxoSmithKline ($GSK) of breaching their marketing agreement on the restless legs syndrome drug Horizant by failing to maximize sales. Story

> The U.K.'s cost-effectiveness watchdogs gave a final rebuff to three colorectal cancer treatments: Merck KGaA's Erbitux, Roche's ($RHHBY) Avastin and Amgen's ($AMGN) Vectibix. News

> A Kaiser Permanente study found Merck's ($MRK) human papillomavirus vaccine Gardasil does not trigger autoimmune disorders. Release

> GlaxoSmithKline's health drink Horlicks outsells Pepsi two-to-one in India, and it's slated for a big emerging-markets push, a company executive says. Article

> Eli Lilly's ($LLY) animal health division Elanco agreed to buy the privately held food-enzyme maker ChemGen for an undisclosed sum. Report

> Biocon expects higher licensing revenues in its pharmaceuticals business after a year-over-year drop in fiscal third-quarter income in that area. Article

> South Korea's Hanmi inked a deal to supply 13 over-the-counter products to the Mongolian market in partnership with domestic pharma MEIC. News

> Jazz Pharmaceuticals shuffled its management team in the wake of its recently closed merger with Azur Pharma. Release

> CEO chair changes hands at Swiss pharma supplier Lonza, after 2011 profits drop by one-third. Report

Biotech News

@FierceBiotech: Roche's hostile Illumina bid highlights two hot trends in biopharma. News | Follow @FierceBiotech

@JohnCFierce: New research links children's exposure to PFCs--found all over the place--with lowered immune response to vaccines. Article | Follow @JohnCFierce

@MarkHFierce: Adult stem cells helped build a better rat penis. You read that right. More | Follow @MarkHFierce

> NEA turns to Europe in $30M round for RNA-drug developer Prosensa. News

> BioLineRx shares pop on hep C pact, raising temps in an overheated field. Story

> Lilly bows out of early-stage R&D joint venture with India's Jubilant. Article

Medical Device News

> Medtronic concludes enrollment in 'extreme risk' study of CoreValve. Item

> Roche looks to snatch up Illumina for $5.7B. More

Drug Delivery News

> Report: Roche transferring Israeli diabetes operations to Europe. Story

> Next-gen nanoparticles deliver cancer drugs at just the right moment. Article

> Mylan concocts ready-to-use epilepsy drug variation. News

> University of Arkansas heightens nanomedicine research efforts. Item

Biomarkers News

> Blood test could predict kidney disease 10 years early. Story

> Quintiles helps form personalized medicine joint venture. News

> Researchers fingerprint head, neck cancer for better diagnostics. Article

> Crosswords, reading cut Alzheimer's biomarker. More

And Finally... Cold-activated brown fat goes into calorie-burning overdrive when people get cold, researchers find. Story

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.